Proliferative_activity_of_neuroendocrine_tumours_of_the_gastroenteropancreatic_endocrine_system:_DNA_flow_cytometric_and_immunohistological_investigations._The_proliferative_activity_of_16_tumour_specimens_from_13_patients_with_neuroendocrine_tumours_of_the_gastroenteropancreatic_endocrine_system_was_studied_by_DNA_flow_cytometry_and_immunohistology_for_the_nuclear_Ki67_proliferation_antigen._Equivalent_results_were_obtained_with_both_methods,_which_showed_the_proliferative_activity_of_gastroenteropancreatic_neuroendocrine_tumours_to_be_heterogeneous._In_four_malignant_small_intestinal_carcinoids_and_one_extravisceral_carcinoid_localised_in_the_retroperitoneum_the_percentage_(index)_of_proliferating_tumour_cells_as_measured_by_DNA_flow_cytometry_ranged_from_2.9_to_36.2%_corresponding_to_low,_moderate,_or_high_proliferative_activity._In_four_malignant_pancreatic_endocrine_tumours_and_their_metastases_indices_ranged_from_8.7_to_18.3%,_corresponding_to_low,_moderate,_or_high_proliferative_activity._In_four_benign_pancreatic_endocrine_tumours_indices_ranged_from_4.3_to_7.7%,_all_corresponding_to_low_proliferative_activity._This_heterogeneity_of_proliferative_activity_may_in_part_explain_the_heterogeneous_results_reported_of_chemotherapy_treatment._As_chemotherapy_of_tumours_is_largely_affected_by_favourable_cell_cycling_kinetics,_individual_diagnostic_investigations_of_the_proliferative_activity_of_these_neuroendocrine_tumours_may_be_of_value_for_identifying_patients_suitable_for_this_treatment.